Diligence memo · auto-generated · as of July 2, 2026
Avidity Biosciences, Inc.
Avidity Biosciences, Inc. has raised $528M over 4 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Avidity Biosciences, Inc. operates in Biotechnology, based in San Diego.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Avidity Biosciences, Inc. has raised $528M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $400M on 2024-03-04.
Most recent recorded round closed around 2024-03-04.
Valuation (modeled)modeled
Provath models Avidity Biosciences, Inc. at approximately $5.7B (range $2.5B–$7.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 30 months.
Last raise 2.3 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 4.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: ImmunityBio, Inc., Denali Therapeutics Inc., Inhibrx, Inc..
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.